NCT06851221View on ClinicalTrials.gov

Β3-adrenoreceptor As Prognostic Marker in Neuroblastoma and Ewing Sarcoma

NACompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

August 5, 2020

Primary Completion Date

March 5, 2024

Study Completion Date

March 5, 2024

Conditions
NeuroblastomaEwing Sarcoma
Interventions
DIAGNOSTIC_TEST

beta3 expression

the samples leftover from the standard diagnostic procedures will be analyzed for the expression of the beta3-adrenoreceptor

Trial Locations (1)

50139

Laboratorio traslazionale in oncoematologia, Florence

All Listed Sponsors
lead

Meyer Children's Hospital IRCCS

OTHER

NCT06851221 - Β3-adrenoreceptor As Prognostic Marker in Neuroblastoma and Ewing Sarcoma | Biotech Hunter | Biotech Hunter